CYP2D6 testing for breast cancer patients: is there more to the story?
Henry
N Lynn
NL
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, USA.
Hayes
Daniel F
DF
Rae
James M
JM
D015415:Biomarkers; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D004344:Drug Incompatibility; D005260:Female; D006801:Humans; D055118:Medication Adherence; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D057285:Precision Medicine; D020845:Selective Estrogen Receptor Modulators / Q000378:metabolism* / Q000627:therapeutic use; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use
D015415:Biomarkers; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; C055492:4-hydroxy-N-desmethyltamoxifen; D019389:Cytochrome P-450 CYP2D6